Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rosuvastatin: do we need another statin?

C Ho

    Issues in Emerging Health Technologies
    |January 5, 2002
    PubMed
    Summary
    This summary is machine-generated.

    Rosuvastatin shows potential for significant cholesterol reduction in hypercholesterolemic patients. However, more research is needed to confirm its safety and long-term cardiac benefits compared to existing statins.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Investigating fine-tuning versus zero-shot learning for general large language models when predicting cancer survival from initial oncology consultation documents.

    ESMO real world data and digital oncology·2026
    Same author

    Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Haematopoietic Stem Cell Transplantation for Relapsed/Refractory Large B-cell Lymphoma.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2025
    Same author

    Clinical errors and mistakes: civil or criminal liability?

    Hong Kong medical journal = Xianggang yi xue za zhi·2025
    Same author

    Can generative AI improve the readability of patient education materials at a radiology practice?

    Clinical radiology·2024
    Same author

    Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2024
    Same author

    Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2023
    Same journal

    Laparoscopic diaphragm pacing for tetraplegia.

    Issues in emerging health technologies·2009
    Same journal

    Implantable hemodynamic monitoring (the Chronicle IHM system): remote telemonitoring for patients with heart failure.

    Issues in emerging health technologies·2008
    Same journal

    Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease.

    Issues in emerging health technologies·2008
    Same journal

    Continuous erythropoietin receptor activator (Mircera) for renal anemia.

    Issues in emerging health technologies·2008
    Same journal

    Milnacipran for fibromyalgia.

    Issues in emerging health technologies·2008
    Same journal

    Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.

    Issues in emerging health technologies·2007
    See all related articles

    Area of Science:

    • Pharmacology
    • Cardiovascular Medicine
    • Clinical Trials

    Background:

    • Coronary heart disease is a leading cause of mortality, often linked to lipid disorders.
    • Statins are a cornerstone therapy for managing dyslipidemia and reducing cardiovascular risk.
    • Rosuvastatin represents a novel synthetic agent developed for lipid management.

    Purpose of the Study:

    • To evaluate the efficacy of rosuvastatin in reducing lipid levels.
    • To compare the lipid-lowering effects of rosuvastatin with other statins.
    • To assess the current regulatory status and clinical trial progress of rosuvastatin.

    Main Methods:

    • Review of limited clinical trial data on rosuvastatin.
    • Analysis of dose-dependent effects on lipid profiles.

    Related Experiment Videos

  • Monitoring of regulatory submissions and approvals.

    • Main Results:

    • Preliminary data suggest rosuvastatin may achieve greater dose-dependent reductions in total cholesterol and LDL-cholesterol compared to other statins.
    • Rosuvastatin is currently in phase III clinical trials, with a New Drug Application submitted to the FDA in June 2001.
    • Regulatory status in Canada is not yet available.

    Conclusions:

    • Rosuvastatin shows promise for potent lipid reduction in hypercholesterolemic individuals.
    • Insufficient evidence currently exists to establish the safety profile of rosuvastatin.
    • Further clinical experience is necessary to determine the effectiveness, safety, and impact on cardiac morbidity and mortality of rosuvastatin therapy.